An engineered stem cell remedy reversed new-onset Kind 1 diabetes in mice by shifting the immune system away from attacking insulin-producing cells.
For greater than a century, individuals with Kind 1 diabetes have relied on insulin to outlive, however the therapy doesn’t cease the immune system from persevering with its assault on the physique’s insulin-producing cells. Scientists have lengthy searched for tactics to deal with the underlying explanation for the illness moderately than merely managing its signs.
Now, researchers on the Medical College of South Carolina (MUSC) report an experimental stem cell remedy that reversed newly identified Kind 1 diabetes in a mouse mannequin. The therapy, described in Molecular Remedy, was designed to reprogram the immune system and defend the insulin-producing cells that stay after illness onset, providing a possible new technique for combating the autoimmune dysfunction.
The work was led by Hongjun Wang, Ph.D., affiliate director of the South Carolina Medical & Translational Analysis (SCTR) Institute Pilot Program and co-scientific director of the Heart for Mobile Remedy. Co-first authors Hua Wei, Ph.D.; Judong Kim, Ph.D.; and Wenyu Gou, Ph.D., along with different collaborators, carried out a lot of the analysis behind the findings.
“Whereas insulin injections are lifesaving, they can’t cease immune assaults, and they don’t stop long-term issues,” mentioned Wang. “This examine suggests a brand new solution to deal with Kind 1 diabetes by addressing the basis trigger – immune system dysfunction –moderately than simply managing blood sugar.”
The remedy relies on mesenchymal stem/stromal cells (MSCs), grownup stem cells that may assist restore tissue and regulate immune exercise. Earlier scientific trials have instructed that customary MSCs might assist protect the insulin manufacturing that continues to be in individuals with T1D. The problem is that the physique’s intense inflammatory response can overpower these cells earlier than they can reverse established illness.
To make the cells extra resilient, Wang’s staff engineered MSCs to supply alpha-1 antitrypsin (AAT), a protecting protein that helps defend towards irritation. The modified AAT-MSCs seem to work in two methods without delay, defending surviving insulin-producing cells within the pancreas whereas additionally lowering the overactive immune assault. Co-senior creator Charlie Unusual, M.D., emphasised that this mixed impact makes AAT-MSC therapy stronger than customary stem cell remedy.
Reprogramming the immune system
Wang’s staff subsequent investigated how the therapy was performing contained in the immune system. After analyzing hundreds of particular person immune cells, they discovered that AAT-MSC infusion did greater than quiet an overactive immune response. It appeared to reshape how the immune system behaved.
The remedy impacts two opposing immune cell teams. T-regulatory cells act as peacekeepers, serving to protect insulin manufacturing within the pancreas, whereas CD8+ killer T-cells drive the assault that destroys insulin-producing cells. In T1D, the protecting cells are current, however they’re overwhelmed by a continuing wave of attacking cells, which finally contributes to the lack of insulin manufacturing.
After therapy with AAT-MSCs, Wang and her staff noticed a pointy rise within the variety of protecting T-regulatory cells and a drop in energetic attacking cells. These attacker cells appeared to have been pushed into exhaustion by the remedy.
One other notable function of the therapy was its sturdiness. The stem cells disappeared from the physique inside hours or days, but the immune system modifications continued.
“To affect or remedy T1D, the stem cells themselves do not must be there,” mentioned Wang. “Which means whenever you administer the cell remedy to sufferers, the impact can final six months to 2 years, as seen in scientific trials utilizing MSCs for a spread of illnesses.” Wang thinks AAT-MSCs might launch microscopic elements that hold defending organs after the cells themselves are gone.
A hopeful future
The examine centered on newly identified diabetes, a interval when sufferers usually tend to nonetheless have insulin-producing cells that may doubtlessly be saved. The Wang staff is now evaluating the security and effectiveness of MSCs in sufferers with newly identified Kind 1 diabetes in a scientific trial. Wang’s earlier work on this space was supported by a SCTR Discovery Grant.
The findings may have relevance past diabetes. Wang and her colleagues are already learning whether or not the same immune reprogramming strategy may very well be helpful for different inflammatory and autoimmune illnesses, together with lupus and power pancreatitis.
Extra analysis remains to be wanted earlier than this therapy can advance into broader scientific testing, however the outcomes level to a doable new course for diabetes care.
“If preliminary trials are profitable, we wish to do a big, multicenter trial for Kind 1 diabetes,” mentioned Wang. “The excellent news is that there are research saying that even if in case you have had T1D for a few years, you continue to have remaining insulin-producing cells there which might be functioning. So hopefully we are able to apply this to individuals with long-term T1D as properly.”
Reference: “Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes” by Hua Wei, Wenyu Gou, Judong Kim, Suganya Subramanian, Tiffany Yeung, Paramita Chakraborty, Ahmed Lotfy, Shikhar Mehrotra, Stefano Berto, Charlie Unusual and Hongjun Wang, 30 March 2026, Molecular Remedy.
DOI: 10.1016/j.ymthe.2026.03.032
